Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation
M Schmidt-Hieber, D Teschner… - Expert review of anti …, 2019 - Taylor & Francis
Introduction: Infections are among the most frequent complications in patients with
hematological and oncological diseases. They might be classified as fever of unknown …
hematological and oncological diseases. They might be classified as fever of unknown …
Implementation of a new blood cultures sampling strategy in patients receiving intensive chemotherapy for acute leukemia and/or hematopoietic cell transplantation
C Declerck, A Giltat, R Boutemy… - Leukemia & …, 2023 - Taylor & Francis
Fever is frequent during intensive chemotherapy for patients with hematological
malignancies, and although a pathogen is identified in only 25% of cases, the recognition of …
malignancies, and although a pathogen is identified in only 25% of cases, the recognition of …
Therapie von Infektionen bei Tumorpatienten
M Schmidt-Hieber, D Teschner, M Desole… - … Onkologie: Standards in …, 2022 - Springer
Infektionen gehören zu den häufigsten Komplikationen bei Tumorpatienten und werden in
Fieber unbekannter Ursache („fever of unknown origin “, FUO) sowie klinisch bzw …
Fieber unbekannter Ursache („fever of unknown origin “, FUO) sowie klinisch bzw …
Adjunctive gentamicin did not improve outcome of enterococcal bacteraemia in neutropenic patients: a propensity scored matched study
Background: Patients with haematologic malignancies receiving chemotherapy have a high
risk of developing febrile neutropenia and bloodstream infections. The benefit of adjunctive …
risk of developing febrile neutropenia and bloodstream infections. The benefit of adjunctive …